-DOCSTART- -X- O
Malignant -X- _ B-Patient
brain -X- _ I-Patient
tumors -X- _ I-Patient
continue -X- _ O
to -X- _ O
represent -X- _ O
a -X- _ O
devastating -X- _ O
diagnosis -X- _ O
with -X- _ O
no -X- _ O
real -X- _ O
chance -X- _ O
for -X- _ O
cure. -X- _ O
Despite -X- _ O
an -X- _ O
increasing -X- _ O
list -X- _ O
of -X- _ O
potential -X- _ O
salvage -X- _ O
therapies -X- _ O
, -X- _ O
standard-of-care -X- _ B-Outcome
for -X- _ I-Outcome
these -X- _ I-Outcome
patients -X- _ I-Outcome
has -X- _ I-Outcome
not -X- _ I-Outcome
changed -X- _ I-Outcome
in -X- _ I-Outcome
over -X- _ I-Outcome
a -X- _ I-Outcome
decade. -X- _ I-Outcome
Immunotherapy -X- _ B-Intervention
has -X- _ O
been -X- _ O
seen -X- _ O
as -X- _ O
an -X- _ O
exciting -X- _ O
option -X- _ O
, -X- _ O
with -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
offer -X- _ O
specific -X- _ O
and -X- _ O
long -X- _ O
lasting -X- _ O
tumor -X- _ O
clearance. -X- _ O
The -X- _ O
“gold -X- _ O
standard” -X- _ O
in -X- _ O
immunotherapy -X- _ B-Intervention
has -X- _ O
been -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
a -X- _ O
tumor-specific -X- _ B-Intervention
CD8 -X- _ I-Intervention
T -X- _ I-Intervention
cell -X- _ I-Intervention
response -X- _ I-Intervention
to -X- _ O
potentiate -X- _ O
tumor -X- _ O
clearance -X- _ O
and -X- _ O
immunological -X- _ B-Outcome
memory. -X- _ I-Outcome
While -X- _ O
many -X- _ O
advances -X- _ O
have -X- _ O
been -X- _ O
made -X- _ O
in -X- _ O
the -X- _ O
field -X- _ O
of -X- _ O
immunotherapy -X- _ B-Intervention
, -X- _ O
few -X- _ O
therapies -X- _ O
have -X- _ O
seen -X- _ O
true -X- _ O
success. -X- _ O
Many -X- _ O
of -X- _ O
the -X- _ O
same -X- _ O
principles -X- _ O
used -X- _ O
to -X- _ O
develop -X- _ O
immunotherapy -X- _ B-Intervention
in -X- _ O
tumors -X- _ O
of -X- _ O
the -X- _ O
peripheral -X- _ O
organs -X- _ O
have -X- _ O
been -X- _ O
applied -X- _ O
to -X- _ O
brain -X- _ O
tumor -X- _ O
immunotherapy. -X- _ B-Intervention
The -X- _ O
immune-specialized -X- _ O
nature -X- _ O
of -X- _ O
the -X- _ O
brain -X- _ O
should -X- _ O
call -X- _ O
into -X- _ O
question -X- _ O
whether -X- _ O
this -X- _ O
approach -X- _ O
is -X- _ O
appropriate. -X- _ O
Recent -X- _ O
results -X- _ O
from -X- _ O
our -X- _ O
own -X- _ O
experiments -X- _ O
require -X- _ O
a -X- _ O
rethinking -X- _ O
of -X- _ O
current -X- _ O
dogma. -X- _ O
Perhaps -X- _ O
a -X- _ O
CD8 -X- _ O
T -X- _ O
cell -X- _ O
response -X- _ O
is -X- _ O
not -X- _ O
sufficient -X- _ O
for -X- _ O
an -X- _ O
organ -X- _ O
as -X- _ O
immunologically -X- _ O
unique -X- _ O
as -X- _ O
the -X- _ O
brain. -X- _ O
Examination -X- _ O
of -X- _ O
previously -X- _ O
elucidated -X- _ O
principles -X- _ O
of -X- _ O
the -X- _ O
brain’s -X- _ O
immune-specialized -X- _ O
status -X- _ O
and -X- _ O
known -X- _ O
immunological -X- _ O
preferences -X- _ O
should -X- _ O
generate -X- _ O
discussion -X- _ O
and -X- _ O
experimentation -X- _ O
to -X- _ O
address -X- _ O
the -X- _ O
failure -X- _ O
of -X- _ O
current -X- _ O
therapies -X- _ O
. -X- _ O

